Tivozanib单药治疗ICI后RCC的疗效优于联合疗法

IF 12.1 1区 医学 Q1 UROLOGY & NEPHROLOGY
Maria Chiara Masone
{"title":"Tivozanib单药治疗ICI后RCC的疗效优于联合疗法","authors":"Maria Chiara Masone","doi":"10.1038/s41585-024-00971-y","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":19088,"journal":{"name":"Nature Reviews Urology","volume":"21 12","pages":"706-706"},"PeriodicalIF":12.1000,"publicationDate":"2024-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Tivozanib monotherapy outperforms combination therapy in post-ICI RCC\",\"authors\":\"Maria Chiara Masone\",\"doi\":\"10.1038/s41585-024-00971-y\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":19088,\"journal\":{\"name\":\"Nature Reviews Urology\",\"volume\":\"21 12\",\"pages\":\"706-706\"},\"PeriodicalIF\":12.1000,\"publicationDate\":\"2024-11-11\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Nature Reviews Urology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.nature.com/articles/s41585-024-00971-y\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"UROLOGY & NEPHROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nature Reviews Urology","FirstCategoryId":"3","ListUrlMain":"https://www.nature.com/articles/s41585-024-00971-y","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0

摘要

TiNivo-2是一项多中心、随机III期试验,旨在评估血管内皮生长因子受体抑制剂tivozanib单药与免疫检查点抑制剂(ICI)nivolumab联合治疗晚期肾细胞癌(RCC)患者的疗效,这些患者在既往1-2种疗法(包括一种ICI)期间或之后出现进展。单药治疗组患者的无进展生存期(PFS)(7.4个月)高于联合治疗组患者(5.7个月;HR 1.10,95% CI 0.84-1.43;P = 0.49)。这些结果表明,让晚期RCC患者再次接受ICI治疗并不可取,并建议在ICI治疗后将替伏扎尼单药疗法作为一种可行的治疗方案。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Tivozanib monotherapy outperforms combination therapy in post-ICI RCC
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Nature Reviews Urology
Nature Reviews Urology 医学-泌尿学与肾脏学
CiteScore
12.50
自引率
2.60%
发文量
123
审稿时长
6-12 weeks
期刊介绍: Nature Reviews Urology is part of the Nature Reviews portfolio of journals.Nature Reviews' basic, translational and clinical content is written by internationally renowned basic and clinical academics and researchers. This journal targeted readers in the biological and medical sciences, from the postgraduate level upwards, aiming to be accessible to professionals in any biological or medical discipline. The journal features authoritative In-depth Reviews providing up-to-date information on topics within a field's history and development. Perspectives, News & Views articles, and the Research Highlights section offer topical discussions and opinions, filtering primary research from various medical journals. Covering a wide range of subjects, including andrology, urologic oncology, and imaging, Nature Reviews provides valuable insights for practitioners, researchers, and academics within urology and related fields.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信